Introduction
Rheumatoid arthritis (RA) is a chronic, systemic autoimmune disease of unknown origin that targets the joints, resulting in inflammation and in the eventual destruction of cartilage and bone. In RA, this destructive arthropathy is the end result of a milieu of highly inflammatory cytokines and chemokines, including tumor necrosis factor-a, interleukin-1 (IL-1), IL-8 and monocyte chemoattractant protein-1 (Pope, 2002) . Once the resident cells in the joint have begun to create this toxic inflammatory environment, a positive feedback loop is created. The influx of cytokines results in the recruitment of additional inflammatory cytokine-and chemokine-producing cells, such as lymphocytes and monocytes, the induction of angiogenesis and in synovial fibroblast proliferation. These in turn lead to an increased production of more inflammatory cytokines, and thus to further amplified pathogenesis. Although the exact cause of disease progression leading to bone destruction is currently unknown, it is clear that the severity of disease is related to the overabundance of inflammatory cells in the joint, and that chronic disease may be a result of a prolonged lifespan of these cells by the dysregulation of apoptosis. The anti-apoptotic protein Mcl-1 has recently been shown to be upregulated in RA macrophages and in synovial fibroblasts (Liu et al., 2005 . Meanwhile, Bim and Bid, both BH3-only pro-apoptotic initiator proteins, have been shown to protect against the prolonged persistence of inflammatory arthritis in a mouse model (Scatizzi et al., 2006 (Scatizzi et al., , 2007 . With expanding evidence that multiple apoptotic regulators are responsible for protecting against RA, perhaps by controlling apoptosis, it may be possible to shift the balance back to homeostasis, by causing controlled cell death in the infiltrating cells in the joint, and decrease the severity of disease.
Rheumatoid arthritis disease pathogenesis
Although the exact etiology of RA is currently unclear, several aspects of disease pathogenesis are well characterized. A synovial joint is composed of two bones separated by a synovial membrane, cartilage and a joint cavity filled with synovial fluid. In a normal joint, the synovial lining is 1-2 cell layer thick, and the bone is smooth in appearance. However, in an RA joint, the synovial lining can become hyperplasic, and increase up to 10-12 cell layers thick. In chronic RA, the synovial tissue will eventually invade the cartilage and bone in the joint, forming pannus, and directly (through osteoclast absorption of bone) and indirectly (through the secretion of destructive inflammatory proteases) destroy the surrounding bone and tissue by erosion. Although the presence of numerous proinflammatory cytokines and chemokines, including tumor necrosis factor-a, IL-1b, IL-8 and monocyte chemoattractant protein-1 (Pope, 2002) , as well as other cytokines, such as IL-20 (Hsu et al., 2006) , IL-22 (Ikeuchi et al., 2005) and IL-23 (Murphy et al., 2003; Brennan and Beech, 2007) seems to support the profuse amounts of lymphocytes, macrophages and synovial fibroblasts in the RA joint (Pope, 2002) , this increase in multiple cell types in the RA joint stands in stark contrast to the noxious environment within the diseased joint, in which reactive oxygen species and death-ligand-expressing cells are present in large amounts. In an attempt to explain the increased number of cells within the RA joint, dysregulation of apoptosis became a natural theory.
Although the initial studies detailing the role of apoptosis in RA by investigating the presence of DNA strand breaks proved to be conflicting (Firestein, 1995; Nakajima et al., 1995; Matsumoto et al., 1996; Sugiyama et al., 1996) , the idea that decreased apoptosis helps to produce the large number of cells in the RA joint has been supported by further studies focusing on the examination of cellular morphology and electron microscopy of the RA synovial tissue (Firestein, 1995; Nakajima et al., 1995; Matsumoto et al., 1996; Sugiyama et al., 1996; Pope, 2002) . Increasing the amount of apoptosis in rodent models of arthritis has been reported to decrease disease severity (Fujisawa et al., 1996; Zhang et al., 1997; Miagkov et al., 1998) . Meanwhile, juvenile pauciarticular arthritis patients were found to have increased rates of myeloid cell apoptosis as compared with juvenile patients with polyarticular arthritis (Harjacek et al., 2001) . Taken together, these data suggest that decreased apoptosis may play an important role in the increased cellularity in the RA joint, and that, by increasing the amount of apoptosis in the joint, it is possible to decrease the number of cells in the joint and ease the effects of RA progression.
The role of apoptosis in limiting cellularity in the joint
Apoptosis is a highly conserved cell death process by which cells can be eliminated without destroying the surrounding cells or tissue. Upon apoptotic death, cellular receptors specific for apoptosis are either upregulated or exposed. These receptors are recognized by macrophages, resulting in clearance of the apoptotic cells by phagocytosis. This is in contrast to cell death by necrosis, wherein cells rupture and release their contents upon death (Liu and Pope, 2004) . There are two central mammalian pathways of apoptosis: the extrinsic pathway mediated by death-receptor and death-ligand interactions and the intrinsic pathway mediated by the loss of mitochondrial membrane potential. Briefly, in the extrinsic pathway, recognition of a death receptor by its cognate ligand leads to the recruitment of adaptor proteins and pro-caspases, resulting in the death-inducing signaling complex (Walczak and Sprick, 2001 ). The death-inducing signaling complex, mediated by the close proximity of its component pro-enzymes, leads to the catalysis of caspases 8 and 10, leading to cell death.
The intrinsic apoptosis pathway is mediated by the Bcl-2 protein family. Induction of the intrinsic pathway by a number of cellular stressors results in the disruption of the homeostatic balance between the pro-and antiapoptotic Bcl-2 family members. The increased presence of pro-apoptotic proteins leads to the release of cytochrome C and other apoptogenic molecules (such as Smac/DIABLO) from the mitochondria, resulting in the formation of the apoptosome by cytochrome C, Apaf-1 and pro-caspase 9. The apoptosome acts as a self-propagating signal amplification loop, leading to the autocatalysis of pro-caspase 9 to active caspase 9 and to the eventual death of the cell (Haupt et al., 2003) .
Within the Bcl-2 family, there are both anti-apoptotic proteins (for example, Bcl-2, Bcl-xL, Mcl-1, A1) as well as pro-apoptotic proteins (for example, Bak, Bax, Bad, Bid, Bim, Noxa, Puma). The anti-apoptotic proteins contain three or all four of the Bcl-2 homology domains (BH domains), whereas the pro-apoptotic proteins are further classified into multi-BH (Bak and Bax) and BH3-only domain proteins (Bim, Bid, Noxa, Puma and others) (Adams and Cory, 1998; Youle and Strasser, 2008) . Furthermore, the BH3-only pro-apoptotic proteins are further subdivided into initiator and sensitizer proteins. The initiator proteins, such as Bid and Bim, have an affinity for all of the anti-apoptotic proteins, as well as for Bak and Bax, whereas the sensitizer proteins (Bad, Bik/Blk/Nbk, Bok/Mtd, Hrk/DP5, Bmf, Noxa and Puma/Bbc3) have a more restricted pattern of binding (Wang et al., 1996; Letai et al., 2002; Marani et al., 2002; Chen et al., 2005; Youle and Strasser, 2008) . The BH3-only protein, Bid, also acts as a connection between the extrinsic and intrinsic pathways. In some cell types, the truncation of Bid to tBid by caspase 8 from the extrinsic pathway leads to the translocation of tBid to the mitochondria, where it initiates the intrinsic pathway. In this way, apoptosis is amplified by the activation of both apoptosis pathways (Wang et al., 1996; Li et al., 1998) .
The RA joint contains an inordinate number of lymphocytes, macrophages and synovial fibroblasts (Pope, 2002) . This increase in cell number corresponds with an increased expression of Bcl-2 (Perlman et al., 2000) , Mcl-1 (Liu et al., 2005 and Bcl-xL (Busteed et al., 2006) in the RA synovium as compared with that in normal synovial tissue. Meanwhile, the increased presence of cells with a higher Bcl-2 expression correlates with an increased lining thickness and inflammatory score (Perlman et al., 2000) , and mRNA expression levels of Bcl-2 are higher in RA synovial tissue as compared with that in osteoarthritis synovial tissue (Salmon et al., 1997) . These data are consistent with additional studies in an adjuvant-induced arthritis model in rats, wherein it has been reported that there are increased levels of Bcl-2 at the sites of erosion and inflammation (Perlman et al., 2001) . Taken together, these data strongly suggest that tilting the homeostatic balance toward the anti-apoptotic Bcl-2 family members plays an important role in the increased cellularity of the RA joint and thus in the severity of disease.
BH3-only domain proteins are vital in the maintenance of tolerance in RA
Although there is a preponderance of data suggesting that the apoptotic balance is shifted toward the anti-apoptotic Bcl-2 family members in the RA joint, specific studies focusing on the pro-apoptotic components in the relationship are slightly less well investigated. The multi-domain pro-apoptotic protein, Bax, has been reported to be upregulated in RA synovial tissue as compared with that in control tissue; however, this expression seems to be insufficient to induce apoptosis, and it is unclear whether this represents the active form of Bax (Hilbers et al., 2003) . These data are supported by studies in the K/BxN serum transferinduced model of the effector phase RA in mice, in which both Bak-and Bax-deficient (BakÀ/À or BaxÀ/À) mice on the C57Bl/6 (B6) background displayed no increase in ankle circumference as compared with that in control mice (Scatizzi et al., 2006) . Furthermore, the BH3-only protein, Puma, has been detected in the sublining, but not in the synovial lining region of the joint (Cha et al., 2006) , but this expression does not seem to significantly increase systemic apoptosis within the joint.
Although Bax and Puma expressions are increased in the RA joint despite the overall decrease in apoptosis, the BH3-only protein Bim seems to play an important role in the maintenance of tolerance in RA. Synovial fibroblasts from RA patients, who were treated with Bim-RNAi, failed to undergo apoptosis induction by antisense Mcl-1. Moreover, these Bim-RNAi-treated fibroblasts also displayed a level of apoptosis similar to a more complete blockade of intrinsic apoptosis by treatment with Bak-Bax-RNAi (Liu et al., 2005) . These data suggest that the BH3-only initiator Bim is as important in the maintenance of tolerance in RA as the combined multi-domain pro-apoptotic executioner proteins, Bak and Bax. These data are corroborated by mouse studies in the K/BxN model of arthritis, in which BimÀ/À mice displayed a sustained inflammatory response as compared with B6 control, BakÀ/À or BaxÀ/À mice. This included an increase in ankle swelling 2 days post-serum transfer, which did not resolve by day 7 as in the control mice. Furthermore, histological scoring of BimÀ/À sections on day 7 suggested a decrease in pannus formation, osteoclast function, bone erosion and inflammation (Scatizzi et al., 2006) . Proinflammatory cytokine levels were increased in BimÀ/À over the course of the study, whereas antiinflammatory cytokines were decreased, and fewer apoptotic cells were detected by TUNEL (terminal deoxynucleotidyl transferase dUTP nick end labeling) staining in the joints of the BimÀ/À mice after K/BxN serum transfer when compared with that in B6 mice. BimÀ/À mice also display an increase in the number of circulating peripheral blood inflammatory monocytes (Hutcheson et al., 2005) , a population that is likely to become synovial macrophages during the progression of RA, suggesting a potential role for apoptosis in general, and for Bim specifically, in myeloid cell apoptosis and maintenance of tolerance in RA.
The loss of the BH3-only protein, Bid, has also been reported to result in an increase in K/BxN serum transfer-induced arthritis as displayed by a delay in the onset of the resolution phase of disease (Scatizzi et al., 2007) . Although the end result on day 7 after K/BxN serum transfer is similar to that observed in BimÀ/À mice (Scatizzi et al., 2006) , including increased ankle swelling, increased numbers of neutrophils and macrophages and a decrease in the number of apoptotic cells, there is a lack of proinflammatory cytokines and no significant difference in disease development on day 2 or 4 after serum transfer (Scatizzi et al., 2007) . These data indicate the BH3-only protein, Bid, in limiting the effector phase of inflammatory arthritis; however, the effect seems to be less prominent, potentially as a result of the unique position of Bid at the intersection of the intrinsic and extrinsic apoptosis pathways.
Function and regulation of Bim
The pro-apoptotic BH3-only protein is a potent initiator of apoptosis, responding to a number of apoptotic stimuli in a wide range of cell types, including hematopoietic cells, neurons, epithelial cells, endothelial cells, osteoclasts, mast cells and germ cells (O 'Reilly et al., 2000; Akiyama et al., 2003; Alfredsson et al., 2005; Ley et al., 2005; Hughes et al., 2006; Youle and Strasser, 2008) . At homeostasis, Bim can be bound to the dynein motor complex through the dynein light chain (Puthalakath et al., 1999), thus keeping Bim separate from the mitochondria and other pro-apoptotic proteins, and thereby preserving the mitochondial membrane. However, in the presence of apoptotic stimuli, Bim is allowed to translocate to the mitochondria, where, it is theorized, it interacts with anti-apoptotic proteins, to which Bim has global affinity (Chen et al., 2005) , neutralizing their prosurvival effects. It is also clear that Bim is upstream in the intrinsic apoptosis pathway from the multi-domain proteins, Bak and Bax, as the concomitant loss of Bim and Bak or Bax, results in more profound phenotypes than does the loss of Bim, Bak or Bax singularly (Hutcheson et al., 2005) .
As Bim has such a wide range of pro-apoptotic targets, there would be the potential for massive amounts of apoptosis without sufficient checks and balances. As such, Bim can be modified both on a transcriptional and on a post-translational level. Although there are varying reports on how the transcription of Bim is increased by the JNK family members (Putcha et al., 2001; Whitfield et al., 2001) , Bim mRNA and protein expressions have been shown to be increased after cytokine withdrawal as a result of the forkhead-like transcription factor, FOXO3A (Dijkers et al., 2000) . After translation, Bim is regulated primarily by its ubiquitination state. Phosphorylation of Bim increases ubiquitination and proteosomal degradation of Bim, leading to an increase in cell survival, whereas growth factor withdrawal in osteoclasts results in a decrease in ubiquitination, a decrease in proteosomal degradation of Bim and a predilection for cell survival (Hughes et al., 2006) .
As Bim is expressed in such a wide range of cell types, including hematopoietic cells, and as it is capable of targeting all of the known anti-apoptotic proteins, it is not surprising that Bim is vital for maintaining homeostasis in a number of cell types, with global Bim deficiency (BimÀ/À) resulting in increased numbers of lymphocytes as well as myeloid cells (Hutcheson et al., 2005) . Furthermore, Bim acts to protect against the development of autoimmunity. As mice deficient for Bim age, they develop hypergammaglobulinemia and high titers of autoantibodies, symptoms similar to human systemic lupus erythematosus. Although this phenotype is slightly muted on the generally autoimmunity-resistant C57Bl/6 background, further loss of Fas, in addition to Bim deficiency, leads to the development of splenomegaly, lymphadenopathy, increased autoantibodies and significantly increased kidney pathology by 4 months of age in female mice (Hutcheson et al., 2008) . Furthermore, on the C57Bl/6 x129-mixed background, approximately half of the BimÀ/À mice succumb to a fatal autoimmune disease characterized by proliferative glomerulonephritis with immune complex deposition by 1 year of age .
Bim as a regulator of autoimmunity
Perhaps unsurprisingly, considering the wide distribution of Bim and the vital role it plays in the initiation of apoptosis, multiple cell types are affected by the dysregulation of Bim expression, resulting in the aforementioned autoimmune phenotypes. In fact, Bim has been shown to be required for the deletion of autoreactive thymocytes Villunger et al., 2004) , with an abnormal accumulation of mature CD4, CD8 double-negative thymocytes in Bim-deficient mice . Bim has also been found to be required for the deletion of mature T cells (Davey et al., 2002) . Beyond its role in the development of T cells, Bim also plays a critical role in the shutdown of the T-cell response, as evidenced by the increased survival of BimÀ/À CD4 þ and CD8 þ T cells following Staphylococcus aureus enterotoxin B activation as compared with that in wild-type cells (Hildeman et al., 2002) and with a prolonged survival of activated CD8 þ T cells in Bimdeficient mice infected with herpes simplex virus (Pellegrini et al., 2003) . Taken together, these data suggest that Bim is critical for the proper development, shutdown and deletion of T cells, which are found in large numbers in the synovium. Thus, dysregulation of Bim could lead to unchecked T-cell proliferation, leading to the production of proinflammatory cytokines found in the RA joint (including IL-17 and IFN-g (Firestein, 2003; Brennan and Beech, 2007) ) and to the recruitment of additional immune effector cells to the RA joint.
Bim is also necessary for the proper regulation of B-cell deletion, both during development in the bone marrow as well as in the periphery (Enders et al., 2003) , as well as for germinal center-derived memory B cells and antibody-forming cells (Fischer et al., 2007) . Furthermore, BAFF (B-cell activating factor belonging to the tumor necrosis factor family) regulates B-cell survival by downregulating Bim through the ERK signaling pathway (Fischer et al., 2007) , resulting in a loss of B-cell anergy (Oliver et al., 2006) . This relationship between Bim and B-cell deletion is important with regard to the pathogenesis of RA, because B-celldepletion therapy is efficacious to some degree in the treatment of the disease (Edwards et al., 2004; Bugatti et al., 2007) . Aside from the production of autoantibodies, including the RF factor and anti-citrullinated antibodies, B cells can play a role in the pathogenesis of RA by mediating B-and T-cell interactions, as well as by producing cytokines that can influence the proinflammatory environment, including the alteration of Th1/Th2T-cell populations (Bugatti et al., 2007) .
Macrophages are central to the pathogenesis of RA. Monocytes from the peripheral blood differentiate into synovial macrophages in the joint. These macrophages come in two varieties-type A synoviocytes in the synovial lining and interstitial macrophages distributed throughout the synovium. These cells are key producers of a number of proinflammatory cytokines, including IL-1, IL-6, IL-8, IL-12, IL-15 and IL-18. Furthermore, additional inflammation is mediated by macrophages secreting chemoattractant chemokines, such as monocyte chemoattractant protein-1, MIP-1a, RANTES, PARC and fractalkine (Szekanecz and Koch, 2007) . Clearly, monocytes and their derivative macrophages can play a sizable role in shifting the balance of the RA joint toward proinflammatory conditions. Furthermore, it has been shown earlier that expression of the antiapoptotic protein, Mcl-1, is increased in RA macrophages as compared with that in normal cells . This suggests a potential direct link between macrophages and apoptosis in RA. The development of osteoclasts from monocyte-lineage cells further increases the importance of myeloid cells in the pathogenesis of RA, as osteoclasts are responsible for the destruction of the subchondral bone. Bim has been shown to play a critical role in the maintenance of both osteoclast survival and activity (Akiyama et al., 2003; Wakeyama et al., 2007) . Furthermore, the loss of Bim has been shown to increase the number of circulating peripheral blood monocytes (Hutcheson et al., 2005) and the amount of proinflammatory cytokines in the joints of mice following the induction of K/BxN serum transferinduced arthritis (Scatizzi et al., 2006) . T cells, B cells, myeloid cells, including macrophages, synovial fibroblasts and osteoclasts are all important cell populations with regard to the pathogenesis of RA. Meanwhile, Bim plays an important role in the maintenance of tolerance in all of these cell types. Taken together, these data suggest that Bim is a viable target for therapeutic intervention in RA.
Function and regulation of Bid and its effect on autoimmunity
Although Bid is similar to Bim, in that it is also a BH3-only pro-apoptotic initiator protein, its role at the crossroads of the extrinsic and intrinsic pathways makes it more complicated to completely define the function of Bid. Bid is widely expressed, with the highest level of expression being present in the kidney (Wang et al., 1996) . Although few studies have focused on the transcriptional control of Bid, it has been found that p53 is a positive regulator, suggesting that Bid plays a critical role in p53-mediated apoptosis, and in fact, BidÀ/À fibroblasts are resistant to DNA damageinduced apoptosis by p53-mediated agents such as adriamycin (Sax et al., 2002) . Full-length Bid has relatively poor pro-apoptotic activity, and in fact, has no amino acid sequence homology with Bak, Bax or Bcl-2-like proteins (Chou et al., 1999; McDonnell et al., 1999) . Thus, Bid must be truncated to tBid by caspase or granzyme-mediated proteolysis (Li et al., 1998; Luo et al., 1998) . Although this often occurs as a result of caspase 8-mediated cleavage, Bid is not required for CD95-induced apoptosis of lymphocytes, suggesting that Bid likely functions as an enhancer of the extrinsic pathway (Yin et al., 1999) . However, Bid-deficient hepatocytes and fibroblasts did display some resistance to death-receptor-mediated apoptosis, suggesting that the role of Bid may be cell type specific (Yin et al., 1999) . Despite caspase 8 being the primary activator of Bid proteolysis to tBid, other caspases can induce a similar effect; moreover, granzyme is also capable of Bid truncation, suggesting that Bid may function in the general amplification of apoptosis under some apoptotic conditions, as well as in perforin-dependent killing by cytotoxic T cells (Sutton et al., 2000; Waterhouse et al., 2005) . Furthermore, Bid plays a role in the maintenance of myeloid homeostasis. Bid-deficient mice are viable and display normal homeostasis in all tissues at an early age. However, as the mice age, that is, around 18-24 months of age, they develop an increased number of neutrophils. Myeloid precursor cells from BidÀ/À mice are resistant to death-receptor-mediated apoptosis and display a competitive advantage in repopulating a marrow compartment (Zinkel et al., 2003) . Although the exact role it plays in the development of experimental RA is unclear, the loss of Bid resulted in a decrease in apoptosis in the joint, suggesting that Bid functions to prolong the survival of macrophages, synoviocytes, osteoclasts and potentially other cell types, perpetuating the development and prolonged regulation of a proinflammatory environment (Scatizzi et al., 2007) . As such, perhaps the targeted tBid could function as a supplementary therapeutic target, though the widespread effects of Bid across both mammalian apoptotic pathways may complicate the effects of any treatment.
BH3-mimetics as potential therapeutics in RA
Recently, several natural and synthetically developed compounds that mimic the function of the BH3 domain of the pro-apoptotic Bcl-2 family have been developed, predominantly for potential therapeutic usage in treating various types of cancers. As it has been reported that some BH3-only proteins play a protective role with regard to RA, these mimetics may also be an effective treatment for autoimmunity, including for RA. A variety of these mimetic compounds have been recently classified, and a handful of these compounds have reached preclinical trials, with both encouraging and discouraging data. ABT-737 is one synthetic BH3-mimetic, designed to target the BH3-binding pocket of Bcl-xL (Oltersdorf et al., 2005) . It has been shown that ABT-737 action requires the presence of Bak and Bax, and thus is most similar to a sensitizing BH3-only protein (Oltersdorf et al., 2005; Labi et al., 2008) . Although the in vivo mouse xenograft tumor models were encouraging (Oltersdorf et al., 2005) , ABT-737 may not be an excellent candidate for the BH3 mimetic treatment of RA, as it has no effect on cells expressing high levels of Mc1-1 (Chen et al., 2005; Konopleva et al., 2006; van Delft et al., 2006) , considering the increased expression of Mcl-1 in RA macrophages. Obatoclax from Gemin X Pharmaceuticals (Montreal, Canada) showed in vitro efficacy in non-small cell lung cancer, mantle cell lymphoma, as well as in multiple myeloma cells, but these data could not be replicated after the xenograft transfer of tumors in vivo (Perez-Galan et al., 2007; Labi et al., 2008) . More recently, obatoclax has been shown to sensitize human cholangiocarcinoma cells by inhibiting Mcl-1 binding to Bak and Bim (Mott et al., 2008) . Furthermore, obatoclax has been reported to affect the expression levels of Bim (Nguyen et al., 2007; Trudel et al., 2007) , and competes with a Bid-BH3 for binding of Mcl-1, Bcl-2 and Bcl-xL in the BH3 binding pocket (Nguyen et al., 2007; Mott et al., 2008) . However, obatoclax is believed to function by disrupting the binding of Bak and Mcl-1 (O'Brien et al., 2008) . As Bak has not been shown to play a predominant role in human RA, and as Bak does not play a role in at least some rodent models of inflammatory arthritis (Scatizzi et al., 2007) , it is possible that obatoclax may not be a suitable BH3 mimetic for RA treatment, although it certainly invites further study.
One interesting option for potential BH3-mimetic treatment of RA is the delivery of a Bim-BH3 peptide. Given that Bim has been shown to play a role in the K/BxN model of inflammatory arthritis (Scatizzi et al., 2006) , and given the large role for Bim in maintaining homeostasis in the immune system (Strasser, 2005; Hughes et al., 2006; Youle and Strasser, 2008) , a mimetic that contains the BH3 region from the Bim protein could be a promising therapeutic agent in RA. Earlier studies have shown that conjugation of the TAT sequence from HIV to the BH3 domain is sufficient to induce apoptotic cell death in multiple cancer cell lines in a dose-dependent manner (Kashiwagi et al., 2007) . Furthermore, the BH3 peptide to Bim has been shown to have an affinity for Mcl-1 (Letai et al., 2002; Chen et al., 2005) . Taken together, these data suggest that TAT-Bim may provide an excellent therapeutic opportunity by allowing the re-establishment of apoptotic homeostasis, resulting in cell death in the RA joint and in the potential alleviation of RA.
Conclusion
A decrease in apoptosis in the joint results in an increase in joint cellularity and local inflammation, leading to the destruction of bone, ligament and cartilage in chronic cases of RA. Although reports have indicated that antiapoptotic Bcl-2 protein levels are increased in the RA joint, there has been little indication that these expression levels are indicative of disease progression, synovial lining thickness or outcome. Meanwhile, in a rodent inflammatory arthritis model that resembles the effector phase of RA, loss of the pro-apoptotic BH3-only domain proteins, Bim and Bid, was shown to prolong the course of disease, whereas the singular loss of either of the multi-domain proteins, Bak and Bax, had no effect on the outcome of disease. These data suggest that an initiator BH3-only protein, such as Bim, may play an important role in protecting against RA. In fact, Bim is critical in the maintenance of tolerance and homeostasis in a wide range of cell types, including immature and mature T, B and myeloid cells, all of which incidentally play a role in the establishment or extension of inflammation in RA. With the rise in the popularity of BH3-mimetic drugs, it seems reasonable to consider that these drugs may be able to have an effect on the course of disease in RA, potentially re-establishing apoptotic homeostasis and preventing further damage in the joint. 
Conflict of interest

